Supplementary Table S1. Clinicopathologic characteristics of study population (69 cases)

Age (years) (median, range)	58.0 (32.0-85.0)
Follow-up period (months) (median, range)	63.0 (12.0-154.0)
Pre-operative CA-125 (U/mL) (median, range)	1198.6 (33.5-27961.5)
BMI (kg/m2) (median, range)	23.0 (17.7-38.8)
	Patient number
FIGO stage	
III	58
IV	11
Tumor Histology	
Serous	61
Non-serous	8
Primary treatment[*]	
PDS + postoperative C/T	60
Neoadjuvant C/T + IDS + postoperative C/T	9
Postoperative residual tumor[#]	
≤ 1cm	49
> 1cm	20
Disease recurrence	
Yes	54
No	15
Patient status	
Disease-related death	22
Alive	47

CA-125, cancer antigen 125; BMI, body mass index; FIGO, the International Federation of Gynecology and Obstetrics; PDS, primary debulking (cytoreductive) surgery; C/T, chemotherapy; IDS, interval debulking (cytoreductive) surgery; +, and

[*]Chemotherapeutic regimens included platinum-based chemotherapy and platinum-based chemotherapy combined with bevacizumab.

[#]Residual tumor status was recorded after debulking (cytoreductive) surgery.